XML 45 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Details) - USD ($)
1 Months Ended 6 Months Ended
Jul. 31, 2017
Mar. 31, 2017
Jun. 30, 2016
Jan. 31, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                
Goodwill         $ 18,358,000,000   $ 18,162,000,000  
Contingent consideration     $ 661,000,000   1,002,000,000 $ 661,000,000 $ 891,000,000 $ 590,000,000
Contingent milestone payment         $ 0 $ 25,000,000    
Vallee SA                
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                
Percentage of business acquired (as percent)   93.50%            
Cash paid for acquisition of business   $ 358,000,000            
Escrow deposit   176,000,000            
Intangible assets   297,000,000            
Deferred tax liabilities noncurrent   95,000,000            
Other net assets   1,000,000            
Noncontrolling interest   25,000,000            
Contingent liabilities   37,000,000            
Indemnification assets   37,000,000            
Goodwill   $ 180,000,000            
Discount rate (as percent)   15.50%            
Acquired finite-lived intangible assets, weighted average useful life   15 years            
Moderna Therapeutics                
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                
Upfront and milestone payments made to collaborative partner     $ 200,000,000          
IOmet Pharma Ltd                
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                
Cash paid for acquisition of business       $ 150,000,000        
Goodwill       $ 57,000,000        
Discount rate (as percent)       10.50%        
Amount of potential future additional payments for milestones, maximum       $ 250,000,000        
Contingent consideration       94,000,000        
In-process research and development (IPR&D)       155,000,000        
Deferred tax assets noncurrent       $ 32,000,000        
Subsequent event | IOmet Pharma Ltd                
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                
Contingent milestone payment $ 100,000,000